Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Highlights 48-Week Data from Open-Label AURION Study at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017)

Business Wire March 27, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  March 22, 2017

Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

Business Wire March 20, 2017

12 Biggest Mid-Day Gainers For Monday

Benzinga.com  March 20, 2017

Don't Let Offerings Blindside Your Thesis

Benzinga.com  March 19, 2017

Aurinia Announces Presentation at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017)

Business Wire March 16, 2017

6 Tweets Tell The Aurinia Pharma Story

Benzinga.com  March 14, 2017

Mid-Morning Market Update: Markets Open Lower; DSW Earnings Beat Views

Benzinga.com  March 14, 2017

Aurinia Prices US$150.5 Million Public Offering of Common Shares

Business Wire March 14, 2017

Aurinia Announces Public Offering of Common Shares

Business Wire March 13, 2017

Aurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights

Business Wire March 9, 2017

Aurinia Announces Acceptance of Voclosporin Late-Breaking Presentation at the National Kidney Foundation 2017 Spring Clinical Meetings

Business Wire March 6, 2017

20 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  March 6, 2017

Mid-Afternoon Market Update: Crude Oil Down 2%; Ameresco Shares Spike Higher

Benzinga.com  March 2, 2017

Aurinia to Present at Cowen and Company 37th Annual Healthcare Conference

Business Wire March 2, 2017

25 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  March 2, 2017

Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study

Business Wire March 1, 2017

Technical Reports on Biotech Stocks -- ZIOPHARM Oncology, Aurinia Pharma, Arena Pharma, and Marinus Pharma

PR Newswire February 28, 2017

Aurinia Announces Results from Japanese Phase I Ethnic Bridging Study for Voclosporin

Business Wire February 14, 2017

Aurinia’s New CEO, Richard Glickman, to Present at Leerink Partners 6th Annual Global Healthcare Conference

Business Wire February 10, 2017